Advisory Services Network’s Rocket Pharmaceuticals RCKT Stock Holding History

Advisory Services Network’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000	Closed	-$3.58K	–	4069
2026 Q1	$3.58K	Buy	+1,000	New	+$3.97K	﹤0.01%	3976
2025 Q4	–	Sell	-1,000	Closed	-$3.26K	–	3703
2025 Q3	$3.26K	Buy	+1,000	New	+$3.15K	﹤0.01%	3668
2024 Q1	–	Sell	-1,000	Closed	-$30K	–	3161
2023 Q4	$30K	Buy	+1,000	New	+$22.1K	﹤0.01%	2299
2023 Q2	–	Sell	-1,000	Closed	-$17.1K	–	3144
2023 Q1	$17.1K	Hold	1,000	–	–	﹤0.01%	2638
2022 Q4	$19.6K	Buy	+1,000	New	+$18.4K	﹤0.01%	2492

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Advisory Services Network's RCKT Position: Q2 2026 in Review

Advisory Services Network sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 1,000 shares — an estimated $3.58K sold.

Advisory Services Network first reported a position in RCKT in Q4 2022 and held it in 5 quarters. The position peaked at $30K in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Advisory Services Network reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 1,000 Rocket Pharmaceuticals shares in Q2 2026, an estimated $3.58K.
Advisory Services Network first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Advisory Services Network's Rocket Pharmaceuticals position peaked at $30K in Q4 2023.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.